AnaptysBio - Home
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Technology
Therapeutic Antibodies
Somatic Hypermutation
SHM Platform
Key Advantages
Publications
Pipeline
Overview
Rosnilimab
ANB032
ANB033
Imsidolimab
Partnerships
Investors / News
Overview
News
Events
Presentations
Goverance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
Job Openings
Core Values
Total Rewards Program Highlights
AnaptysBio Culture
Contact
Toggle
Therapeutic Antibodies
for Severe Disease
March 27, 2023
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent
March 1, 2023
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 27, 2023
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference
About
Technology
Pipeline
Investors
Careers
